Marker Therapeutics Q3 net loss narrows to $2.0 million as grant income falls
Marker Therapeutics reported third quarter 2025 results on November 14, 2025. The net loss narrowed to $2.0 million from $2.3 million a year earlier, but grant income fell to $1.2 million from $1.9 million, and the nine-month net loss widened to $10.5 million from $6.9 million. The company said its cash will fund operations through the third quarter of 2026, assuming no additional grant funds, after raising approximately $10 million through its ATM facility.
Key points
- Q3 2025 grant income was $1.2 million, down from $1.9 million in Q3 2024
- Q3 2025 net loss was $2.0 million ($0.12 per share), versus $2.3 million ($0.26 per share) a year earlier
- Cash and cash equivalents were $17.6 million at September 30, 2025, plus $1.4 million restricted cash
- Nine-month net loss was $10.5 million versus $6.9 million, including a $453,135 loss on early termination of a vendor agreement
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 14, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.